Related Experiment Video
Updated: May 17, 2026

06:55
A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset (Callithrix jacchus)
Published on: February 27, 2018
Ondansetron and dexamethasone in middle ear procedures
Hammad Usmani1, A Quadir, Rehan Asif Siddiqui
1Department of Anaesthesiology, India.
Summary
For middle ear surgery, a combination of ondansetron and dexamethasone significantly reduces postoperative nausea and vomiting compared to either drug alone. This combination therapy offers superior prevention of these common side effects.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Postoperative nausea and vomiting (PONV) is a common complication after middle ear surgery.
- Effective prophylactic strategies are crucial for patient recovery and satisfaction.
Purpose of the Study:
- To compare the efficacy of ondansetron, dexamethasone, and a combination of both in preventing PONV after middle ear surgery.
- To evaluate the safety profile of these prophylactic antiemetic agents.
Main Methods:
- A randomized, double-blind study involving 90 patients undergoing middle ear surgery.
- Patients received ondansetron (0.1 mg/kg), dexamethasone (0.15 mg/kg), or a combination of both drugs 10 minutes prior to general anesthesia induction.
- Standardized anesthetic techniques were used throughout the study.
Main Results:
- The combination of ondansetron and dexamethasone achieved a complete response (no PONV, no rescue antiemetic) in 83% of patients within the first 4 hours post-anesthesia.
- This combination showed significantly higher efficacy compared to ondansetron alone (58%) and dexamethasone alone (55%).
- Similar superior efficacy was observed over the subsequent 20 hours, with 85% complete response for the combination group versus 54% for ondansetron and 47% for dexamethasone.
Conclusions:
- Prophylactic administration of ondansetron plus dexamethasone is superior to monotherapy with either agent for preventing PONV after middle ear surgery.
- The combination therapy demonstrated a favorable safety profile with no clinically significant adverse effects observed.
- This combined approach represents an effective strategy for managing PONV in this surgical population.

